Computational and Structural Evidence for Neurotransmitter-mediated Modulation of the Oligomeric States of Human Insulin in Storage Granules by Palivec, Vladimír et al.
This is an author produced version of Computational and Structural Evidence for 
Neurotransmitter-mediated Modulation of the Oligomeric States of Human Insulin in 
Storage Granules.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/117191/
Article:
Palivec, Vladimír, Viola, Cristina M, Kozak, Mateusz et al. (8 more authors) (2017) 
Computational and Structural Evidence for Neurotransmitter-mediated Modulation of the 
Oligomeric States of Human Insulin in Storage Granules. The Journal of biological 
chemistry. pp. 8342-8355. ISSN 1083-351X 
https://doi.org/10.1074/jbc.M117.775924
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
Computational and structural evidence for neurotransmitter-
mediated modulation of the oligomeric states of human
insulin in storage granules
Received for publication, January 9, 2017, and in revised form, March 23, 2017 Published, Papers in Press, March 27, 2017, DOI 10.1074/jbc.M117.775924
Vladimír Palivec‡, X Cristina M. Viola§, Mateusz Kozak§1, X Timothy R. Ganderton§, Kveˇtoslava Krˇízˇková‡,
Johan P. Turkenburg§, Petra Halusˇková‡, Lenka Zˇáková‡, Jirˇí Jirácˇek‡2, X Pavel Jungwirth‡3, and
X Andrzej M. Brzozowski§4
From the §York Structural Biology Laboratory, Department of Chemistry, University of York, Heslington, York YO10 5DD, United
Kingdom and ‡Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám
2, 166 10 Prague 6, Czech Republic
Edited by Jeffrey E. Pessin
Human insulin is a pivotal protein hormone controllingmetab-
olism, growth, and aging andwhosemalfunctioning underlies dia-
betes, some cancers, and neurodegeneration. Despite its central
position in human physiology, the in vivo oligomeric state and
conformation of insulin in its storage granules in the pancreas
are not known. In contrast,many in vitro structures of hexamers
of this hormone are available and fall into three conformational
states: T6, T3R
f
3, andR6. As there is strong evidence for accumu-
lation of neurotransmitters, such as serotonin and dopamine, in
insulin storage granules in pancreatic -cells, we probed by
molecular dynamics (MD) and protein crystallography (PC) if
these endogenous ligands affect and stabilize insulin oligomers.
Parallel studies independently converged on the observation
that serotonin binds well within the insulin hexamer (site I),
stabilizing it in the T3R3 conformation. Bothmethods indicated
serotonin binding on the hexamer surface (site III) as well.
MD, but not PC, indicated that dopamine was also a good site
III ligand. Some of the PC studies also included arginine,
which may be abundant in insulin granules upon processing
of pro-insulin, and stable T3R3 hexamers loaded with both
serotonin and arginine were obtained. The MD and PC
results were supported further by in solution spectroscopic
studies with R-state-specific chromophore. Our results indi-
cate that the T3R3 oligomer is a plausible insulin pancreatic
storage form, resulting from its complex interplay with
neurotransmitters, and pro-insulin processing products.
These findings may have implications for clinical insulin
formulations.
Insulin is one of the key human protein hormones that is
responsible for the maintenance of metabolic homeostasis,
with an influence on cell proliferation and regulation of aging
(1, 2). Defects in insulin bioavailability or impaired insulin
receptor signaling lead to different pathological conditions
such as diabetes (3–5), cancers (6–8), and Alzheimer’s disease
(9).
Insulin is a 51-amino acid protein consisting of two disulfide-
linked chains (A1-A21, B1-B30) and exerts its functions
through binding as a monomer to the ()2 heterodimer tyro-
sine-kinase-type insulin receptor (IR)5 (10, 11). Insulin is pro-
duced from a single chain pro-insulin and stored in pancreatic
-cells in storage granules (termed large dense core vesicles
(LDCVs)) from which it is released into the bloodstream in
response to elevated blood glucose levels. The first 3D crystal
structure of insulinwas described byHodgkin and coworkers in
1969 (12) in the form of its hexameric assembly (with three and
two-fold rotational symmetry (i.e. trimer of dimers), obtained
in the presence of Zn2 ions. Two Zn2 ions were identified in
the hexamer on its 3-fold axis, being coordinated by 3 imidazole
side chains of HisB10. This and subsequent similar findings
resulted in a generally accepted paradigm that the hexamer is
the storage form of insulin in LDCVs in pancreatic -cells,
whereas upon its release into the bloodstream it dissociates to
monomers, which represent the active form of the enzyme (13).
The pioneering work of D. C. Hodgkin was followed by 3D
descriptions of hundreds of in vitro studied insulin hexamers,
dimers, and monomers (for reviews, see for example Refs.
14–16). However, the actual in vivo storage form of insulin in
pancreatic -cells LDCVs is still not known, and it is extrapo-
lated from its in vitro structures. Surprisingly, there are more
advances into the very elusive nature of insulin/IR interactions
(17, 18) than into the in vivo formof this hormone, investigation
of which presents formidable experimental challenges.
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The in vitro data showed that insulin hexamers can be
grouped into three structurally distinct states/families: T6,
T3R
f
3, and R6 (15, 16), which differ by the conformation of the
B1-B6 N termini of the hormone B-chain (see Fig. 1 and sup-
plemental Fig. S1). In the T6 hexamers, the initial B1-B6 seg-
ments of the B chains are fully extended followed by B7-B10
type II -turns that go into invariant B9-B19 -helices. In con-
trast, the B1-B6 segments acquire an -helical conformation in
the R-state, extending the B9-B19 -helix (19). The insulin Rf3
state is similar to the -helical R6 state; however, the long
R-state B-chain helix is shortened to the B3-B19 segment,
whereas the B1-B3 residues depart (“fray”) from the -helical
fold (20, 21). The TRf transition can be induced by an increase
of, for example, the concentration of Zn2, SCN, andCl ions
(22) or by the presence of phenolic derivatives (e.g. phenol or
similar small cyclic alcohols) at low concentrations (23–25).
The RfR (or full TR) transition can be accomplished by a further
increase of the concentration of phenolic ligands (19, 24). The
octahedral Zn2 coordination is also a signature of the T-state
(assured by threeHisB10 imidazoles and threewatermolecules),
whereas the Zn2 tetrahedral coordination (three HisB10 and,
for example, aCl ion) is typical for theRf/R-states (e.g.Ref. 26).
This coordination switch results from a smaller space above the
Zn2 ion in the R-state that is obstructed there by a longer
B1-B8 helical part of the B9-B19-helix and a newly formed
binding pocket for cyclic alcohols on the dimer interface,
formed by the side chains of A6–7, A9–11, A16, B7, B11, and
B5–7 (the so-called site I, or phenol main-binding site) How-
ever, variations of the Zn2 coordination spheres are also
observed frequently (27).
Although site I is the main binding cavity for all phenol-like
ligands, they have also been identified in other regions of the
hexamers; e.g. site II, formed by side chains B9, B12, B16, B17,
B9, B10, B13; site I/II formed byB10, B14, B16, B17, andB9 (28).
Hexamer surface-exposed (between insulin dimers) phenolic
site III (A14, A17) has been observed as well (29). The serendip-
itous character of the discovery of the phenol-stabilized R-state
resulted from the bactericide-like applications of phenol in
clinical formulations of insulin. Nevertheless, the R-like states
of the hormone have clinical importance, as the Rf/R-trimers/
hexamers are more stable (30). This is mostly due to the slower
Zn2-solventexchange,whichresultsinahigherhexamer-mono-
mer dissociation constant. However, the physiological rele-
vance of T/Rf/R states for an effective insulin/IR binding and for
the storage form of the hormone (e.g. protection against prote-
olysis) is still unknown.
Here, we attempt to shed light on a possible conformation of
the in vivo storage form of insulin in insulin-containing gran-
ules in pancreatic -cells. Although the exact chemical compo-
sition of LDCVs still awaits full characterization, they contain
Zn2 ions and phenolic neurotransmitters such as dopamine
and serotonin, which are involved in regulation of exocytosis of
the granules and insulin release (31–33). Therefore, we hypoth-
esize that both neurotransmitters can bind to, and affect the
structure of insulin hexamers, assembled in the presence of zinc
cations.Weprobe these effects in parallel viamolecular dynam-
ics simulations (MD) and protein X-ray crystallography. These
were further supplemented by spectroscopic studies with the
use of a sensitive chromophore, 4-hydroxy-3-nitrobenzoic acid
(4H3N), which specifically binds to R-state insulin as indicated
by a red shift of its absorption spectrum. Moreover, as arginine
can accumulate in LDCVs upon processing of pro-insulin at its
two Arg-rich sites (34, 35) and as arginine-rich polypeptides
(spermine/spermidine) are used in some insulin injections for-
mulations (36, 37), we also probe the structural effect of this
amino acid on insulin oligomeric assembly.
Both the MD and X-ray serotonin-related studies point
to a stable insulin hexamer-serotonin-site I complex and its
Figure 1. General structural organization of the three main forms of insulin hexamer: T6 (A), T3R
f
3 (B), and R6 (C) in the hexamer top view along its 3-fold
symmetry axis. Insulin B chains are in white, A chains are in pink; the chains of one representative insulin dimer are indicated in A in light blue (B-chains) and
yellow (A-chains). Some N and C termini of one dimer are also indicated in A and only B-chain N termini in B and C, with * corresponding to the symmetry-related
monomer within a dimer. The B1-B8 segments of the B chains that contribute to the largest structural changes in TR transitions are in red (top of the hexamer)
and in green (bottom of the hexamer). The Zn2 ion is in blue. D–F, representative insulin monomers in T, Rf, and R-state, respectively, with a coloring code as in
A–C. Typical, main ligand binding sites I and III in the R insulin form are indicated in C as S1 and S3 respectively.
Structural forms of storage insulin in pancreas
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dynamic associationwith site III. Bothmethodologies excluded
dopamine binding in site I. MD simulations also indicate pref-
erential dopamine over serotonin binding to site III, whereas
solid-state X-ray analyses yields only serotonin-site III com-
plexes. In addition, crystal structures of serotonin-insulin hex-
amers loadedwith arginine have been obtained that underline a
possible more complex, physiological role of insulin-arginine
interactions.
Results concerning site I complexes are corroborated by
4H3N spectroscopic experiments, which provide apparent
binding constants for interaction of insulin hexamers with phe-
nolic ligands and arginine. Our findings thus provide a novel
insight into the storage mechanism of insulin in pancreatic
-cells, also relevant for novel insulin formulations for clinical
applications.
Results
MD simulations of serotonin, dopamine, and phenol binding
in site I
Here, we address the question of whether two neurotrans-
mitters, serotonin and dopamine, can substitute phenol in its
insulin R6 hexamer binding site I. MD simulations were per-
formed for the R6 insulin hexamer, where site I-bound phenol
was systematically replaced with neurotransmitters (each
ligand in two steric-clash-free orientations; see Fig. 2). As
expected, the MD simulations yielded the benchmark phenol-
bound insulin R6-state hexamer (InsPheR6) with a low root
mean square deviation (r.m.s.d.) of 1.6–1.8 Å from the refer-
ence InsPheR6 structure, indicating that the system does not
deviate significantly from the NMR structure during the simu-
lation (Fig. 3).
Both serotonin (InsSerR6) and dopamine (InsDopR6)
complexes with ligands orientation (1) behaved similarly to
InsPheR6, with the backbone r.m.s.d. just above 2 Å. However,
the starting orientation (2) of the ligands led to higher r.m.s.d.
of 2.8 Å (Fig. 2) indicating somewhat larger structural
changes. Amore direct insight into the behavior of the ligand in
site I can be obtained from a direct comparison of their r.m.s.d.
(Fig. 4).
The MD simulations confirm that phenol molecules are
essentially fixed in site I with aminimal dynamic behavior. Two
of the six phenols transiently break HBs (both with CysA6 and
CysA11); however, they remain in site I, eventually reestablish-
ing the original geometry of binding. Similarly, all but one of the
serotoninmolecules in the starting conformation (1) stay in site
I (only one serotonin ligand temporarily leaves this cavity).
However, serotonin in starting geometry (2) as well as dop-
amine in both starting orientations, break most of the crucial
hydrogen bonds. Serotonin, but not dopamine, thus essentially
mimics phenol interactions observed in InsPheR6 with its
charged aminoethyl-group-forming HB with backbone car-
bonyl CO of CysA11, fitting well into the binding site I.
The strength of binding (i.e. the binding free energy and the
corresponding dissociation constant) of phenol and the two
neurotransmitters was calculated using the thermodynamic
integration method (see Table 1). The free energy calculations
confirmed and quantified the pattern observed in directMD sim-
ulations, indicating a similarly strong binding of phenol and sero-
tonin to site I (Kd of 5.4 10
4
M and 8.1 104 M, respectively)
as well as demonstrating a lack of any stable conformation of dop-
amine in this cavity (reflected in a positive binding free energy).
MD simulations of serotonin and dopamine probing the
hexamer surface sites
Initial simulations of the R6 insulin hexamer with six dop-
amine molecules located in the phenolic pockets indicated that
dopamine does not bind strongly to the phenolic pocket. At the
Figure 2. Starting conformations of phenol (A, insulin R6 hexamer shown
for the sake of clarity of the phenolic pocket location), serotonin (B), and
dopamine (B) molecules (depicted by van der Waals spheres) in the phe-
nolic site I pocket (amino acids A6 and A11 involved in the binding are
depicted by a stick model); two initial orientations of serotonin, and dop-
amine were considered.
Figure 3. r.m.s.d. of the protein backbone (heavy atoms) from the insulin
R6 hexamer NMR structure with different phenolic ligands (phenol, dop-
amine, or serotonin). Labels 1 and 2 correspond to the two starting orienta-
tions of the neurotransmitter molecules.
Structural forms of storage insulin in pancreas
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same time, several dopaminemolecules left the phenolic pocket
to bind to the hitherto unexplored site III at the surface of the
insulin hexamer. Therefore, an additional set of calculations
was performed to characterize the binding of neurotransmit-
ters to the surface of the insulin R6 hexamer (for simulation
details, see the supplemental information). These simulations
showed that dopamine binds at three equivalent binding sites in
between the symmetry-related dimers (Fig. 5, top), which cor-
respond to the previously sporadically observed site III. Analo-
gous MD simulations for serotonin showed a similar mode of
binding in site III but with a spatially looser neurotransmitter
distribution, which reflects its weaker binding to this site com-
pared with dopamine (Fig. 5, bottom). Finally, the binding of
neurotransmitters at the surface sites has only aminor effect on
the structure of the hexamer.
Both dopamine and serotonin bind in site III in a pocket
between GluA17 and Tyr14 from neighboring dimers (Fig. 6).
The stronger binding of dopamine over serotonin shown by
free energy calculations (see below) results from its interactions
with TyrA14, a hydrogen bond of the phenolic OH to GluA17,
and a salt bridge between the aminoethyl group and the carbox-
ylic group of GluA17. Similar interactions are present for sero-
tonin; however, the steric fit is not as good as for dopamine.
Dopamine, serotonin, and phenol binding in site III were quan-
tified by evaluation of the binding free energies and the corre-
sponding dissociation constants (Fig. 7 and Table 2) using
the umbrella sampling method, with symmetry and volume
entropy corrections. In contrast to site I, dopamine is the
strongest binder to site III (Kd 4.38  10
3
M), with serotonin
and phenol showing a much weaker affinity for this surface site
(Kd of 2.13  10
1
M and 2.59  101 M, respectively).
Insulin-serotonin crystal complex
The crystal structure of insulin grown in the presence of
serotonin and Zn2 revealed a T3R3 hexamer (referred to here
as InsSerT3R3), with six neurotransmitters and two Zn
2 ions
per hexamer (Fig. 8). The minimum serotonin concentration
that still yielded complex crystals was within the 35–40 mM
range. The asymmetric unit of this crystal contains 14 mole-
cules of insulin, hence providing reliable, independent multi-
copy structural evidence. The hexamer quaternary structure is
indeed T3R3 as the B1-B3 N termini acquire here a more R-like
(fully -helical) fold rather than an Rf, “frayed,” conformation
observed in T3R
f
3 oligomers.
Coordination of both Zn2 ions is tetrahedral regardless of
the R or T protein environment with axial Cl ligands. The
overall fold of InsSerT3R3 is very similar to other T3R
f
3 hexam-
ers. For example, the r.m.s.d. of InsSerT3R3 from complexes
with phenol (PDB ID 1MPJ Ref. 29), Tylenol (PDB ID 1TYL;
Ref. 23), paraben (3 MTH; Ref. 29), and 4-hydroxy-benzamide
(PDB ID 1BEN; Ref. 25) are 0.8911 Å, 0.9886 Å, 0.9105 Å, and
1.1570 Å, respectively. Also, this hexamer is not significantly
different from phenol-free T3R
f
3 hexamers induced by ions
such as SCN (PDB ID2TCI, r.m.s.d. 0.9919Å; Ref. 29) andCl
(PDB ID 1G7A, r.m.s.d. 0.7765 Å (Ref. 38).
Figure 4. r.m.s.d. from simulations of all phenolic ligands (serotonin or dopamine in two orientations) from the phenol-binding pockets in the insulin
R6 hexamers (in total six phenolic ligands per one R6 hexamer). Each line corresponds to the r.m.s.d. of one phenolic ligand from its starting position with
respect to the O atom of CysA6 and the N atom of CysA11 involved in a hydrogen bond. A zero or small value of r.m.s.d. means a strong ligand, R6 hexamer
hydrogen bond, whereas a significant increase of r.m.s.d. indicates breaking of this bond.
Table 1
Standard free energies of binding of phenol, dopamine, and sero-
tonin, molecules to the binding site I (phenolic pocket) together with
the corresponding dissociation constants
Ligand G
b
° K
d
kcal/mol [M]
Phenol 4.49  1.55 5.4  104
Dopamine 1.10  1.73 6.3
Serotonin 4.24  1.87 8.1  104
Structural forms of storage insulin in pancreas
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Serotonin occupies six sites in InsSerT3R3: three phenol
“main” sites I and three hexamer surface sites III. It is tethered
(Fig. 9) into site I via (typical for phenolic ligands)HBs of itsOH
group to -CO of CysA6 (range of 2.41–2.43 Å) and to -NH of
CysA11 (2.93–3.17Å); aweakerHB -OHcontact to -COof SerA9
(3.38–3.41 Å) further stabilizes this phenolic anchor. A signif-
icant HisB5-N2 pyrrole HB (3.46–3.56 Å) contributes to the
immobilization of the serotonin indole ring, which is assisted
further by more subtle van der Waals (hydrophobic) interac-
tions, especially with LeuB17 (3.45–3.59 Å). The aminoethyl
side chain of serotonin points toward the surface of the hex-
amer, i.e. into the space/gap between two 3-fold related
dimers. The -NH amino group of this side chain is hydro-
gen-bonded to O1 of GluB21 (2.55–2.75 Å) and -CO of
CysA11 (2.72–2.79 Å).
In contrast to site I, the serotonin-binding mode to site III is
rather dynamic, indicating its mobility on the InsSerT3R3 sur-
face. Although serotonin is pincered there in a hydrophobic
clamp of TyrA14 ( interactions3.5 Å) and the side chain of
Figure 5. Dopamine (top, red) and serotonin (bottom, magenta) spatial
distributions around the insulin R6 hexamer (top view). The A/B-chains are
in blue and yellow, respectively; the same isodensity value (50 the bulk
concentration) was used for both neurotransmitters. Black circles depict the
site III binding pockets.
Figure 6. Serotonin (top) and dopamine (bottom) binding site III formed
by two adjacent insulin monomers (Chain A/A and Chain B/B). Detailed
structures of amino acids involved in binding (GluA17 and TyrA14) are also
shown.
Figure 7. Free energy profiles of phenolic ligands entering the surface
binding site III.
Table 2
Standard free energies of binding of phenol, dopamine, and serotonin molecules to the binding site III and the corresponding dissociation
constants
W0 is free energy difference directly fromumbrella sampling calculations, ‹	Gsymm
 is hexamer symmetry contribution,	Gvol is volume entropy contribution (with respect
to the standard state at 1 M), 	Gb° is overall standard free energy of binding, and Kd is the corresponding dissociation constant.
Ligand in the binding site III W0 ‹Gsymm
 Gvol Gb° Kd
kcal/mol kcal/mol kcal/mol kcal/mol M
Phenol 1.83  0.28 0.36 1.38  0.22 0.81  0.36 2.59  101
Dopamine 6.23  0.67 0.36 3.2  0.2 3.24  0.70 4.38  103
Serotonin 2.65  0.55 0.36 2.0  0.1 0.92  0.56 2.13  101
Structural forms of storage insulin in pancreas
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LeuA13 (from a symmetry related dimer), the ligands’ electron
density is generally less well defined there. The serotonin phe-
nolic OH group makes hydrogen bond to the O atoms of
GluA17 (2.96–3.44 Å), and it can be stabilized by water-medi-
ated HB to the hydroxyl of TyrA14. The HBs of the GluA17 car-
boxylic side chain to the guanidinium group of ArgB22 (2.75–
2.82 Å) contributes further to the structural stability of the
serotonin-OHenvironment.However, it is evident that the aro-
matic moieties of Tyr14 and serotonin can slide parallel to each
other, indicating further adaptability of this mode of binding.
Relative flexibility of site III is also seen in differentmodes of the
HB network to the -N group of the serotonin aminoethyl side
chain. It is engaged primarily by HBs to the carboxyl side chain
of GluA17 (2.65–2.76 Å) and via a water molecule to ArgB22, but
this network of HBs is prone to disruption due to the flexibility
of the serotonin surface-exposed side chain. In summary, the
GluA14/ArgB22-pair are the 2-fold symmetry-related providers
of HBs to serotonin (one pair to the ligand’s OH group, the
other one to the end of its side chain) in site III, but these HB
networks are not fully symmetrical in overall geometry and
strength due to a non-symmetrical ligand in this site. The swing
of the other (not involved in serotonin binding) TyrA14 side
chain, away from site III, breaks down the 2-fold symmetry of
this interface even further. Finally, we note that all our dop-
amine/insulin co-crystallizations were unsuccessful, likely due
to the oxidation of the ligand, despite the inclusion of some
anti-oxidation agents in the media.
Insulin-serotonin-arginine crystal complex
A similar set of crystallization conditions yielded crystals
of insulin in a ternary complex with serotonin and arginine
Figure 8. Serotonin binding sites in insulin InsSerT3R3 hexamer: top view
(top), side view (bottom) of the hexamer (A-chains in pink, B-chains in
white, Zn2 ions as blue spheres). Sites I and III are indicated; some N and C
termini of A/B-chains (T-state: T, R-state: R) are shown. Serotonin in atom-
colored coded, with C-atoms in yellow.
Figure 9. Serotonin binding sites: top, site I; bottom, site III, in insulin
InsSerT3R3 complex (insulin color-coded as in Fig. 7, with side-chain C-at-
oms in green, water as a red sphere). Dashed lines, HB; *R and *T, correspond
to symmetry-related dimer and T/R state of the monomer, respectively.
Strong HisB5-N2-pyrrole-center contact is also shown.
Structural forms of storage insulin in pancreas
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(referred to here as InsSerArgT3R3). Arginine- and Zn
2-con-
taining crystallizations of insulin were carried out in the pres-
ence and absence of the previously established optimum sero-
tonin concentration (40 mM). Serotonin-arginine-containing
solutions yielded several morphologically different, but crystal-
lographically very isomorphous, crystal forms. Despite their
similarity, two of these forms (f1, f2) (referred to as InsSer-
Argf1-T3R3 and InsSerArgf2-T3R3) are reported here due to a
dynamic (i.e. with high level of disorder) nature of Arg/insulin
binding, hence the need for more independent structural evi-
dence about the nature of these interactions.
Both InsSerArg complexes appear in the T3R3 hexamer state,
with all Zn2 ions in a tetrahedral coordination with Cl as
an axial ion. They are very similar to the InsSerT3R3 complex,
with overall r.m.s.d. values of 0.2193/0.2349 Å between these
structures.
Despite the presence of arginine, the serotonin modes of
binding in sites I are practically the same as in the Ins-Ser com-
plex (Fig. 10). However, the site III shows more significant
structural variety in binding of this neurotransmitter. Some
serotonins in site III are bound in a fashion observed in
InsSerT3R3; however, some of these ligands are flipped in both
InsSerArgT3R3 crystal forms, i.e. the -OH and aminoethyl
groups switch their positions. As both of them benefit from a
similar HB network of symmetrical GluA14/ArgB22 tandems,
the overall HB-connectivity is conserved here as well, with the
exception of the N atom of the aminoethyl side chain. It forms
in some sites III a new HB with the hydroxyl group of TyrA14
(2.67 Å) besidesmaintaining aHB to the side chain of GluA14 as
well.
It has to be stressed that several serotonins in site III and
arginine molecules (see below) in the InsSerArgT3R3 com-
plex have been refined with half-occupancies and, in some
cases, with more arbitrary modeling due to their partial
definition in the electron density maps. This reflects the
dynamic and mobile character of some ligand/hormone in-
teractions in InsSerArgT3R3 hexamers.
Arginine molecules occupy the “T-state-half” of the trimer
(Fig. 11), with their Cmoieties being part of the T-state trimer
surface (on the level with theCl ion), whereas their side chains
point toward the hexamer core, relatively parallel to its central
axis. The aminocarboxy-C groups of Arg have been modeled
in both InsSerArgT3R3 forms with some flipped/alternative
conformations around the C atom.
The dominant stabilizations of the Arg C-end result from
HBsof the carboxyl group to theNHofCysB7 (2.76–3.31Å) and
amino acid amine group to CO of HisB5 (2.86–3.18 Å). How-
ever, it is possible tomodel this part of arginine with alternative
conformations, a likely effect of a dynamic character of these
ligands at the wider, andmore solvent-accessible, T3 side of the
hexamer.
In contrast, theHBs of theArg guanidiniumgroups aremuch
better defined, especially in the InsSerArgf2T3R3 form. One of
their main signatures is the extensive HB network with both
GluB13 and HisB10 residues. Here, the GluB13 O1/O2 atom
forms HBs to Arg N1 (2.11–2.33 Å) and N1 of HisB10 (2.82–
3.14 Å), whereas the second N2 atom of the guanidinium
group is hydrogen-bonded to CO of HisB10 as well (2.71–2.82
Å). The last guanidinium N1 atom locks this group by HB to
the hydroxyl O	 of SerB9. Some of these HBs are broken in the
InsSerArgf1T3R3 form, also indicating the increasedmobility of
this environment, especially some shifting of the arginine par-
allel to the hexamer 3-fold axis.
Determination of ligand Kd values by solution 4H3N assay
The interactions of insulin hexamers with phenol, serotonin,
dopamine, and arginine in solutionwere investigated andquan-
tified by spectroscopic studies, with the 4H3N chromophore,
which binds exclusively to HisB10 sites in the R-state only,
which is associated with the red shift of its absorption spec-
trum.This allows for the determination of the apparent binding
constants (Kd) of selected ligands to insulin hexamers and esti-
mation of the values of their maximum specific binding (Bmax),
which can be considered here as ameasure of the amount of the
R state induced by the ligand. In addition, the Hill coefficients
(h), which indicate the scale of cooperativity (likely very com-
Figure 10. Serotonin and arginine binding sites in insulin InsSerArgT3R3
hexamer: top view (top) and side view (bottom) of the hexamer (labeling
and color-coding as in Fig. 7, with arginine C-atoms in light green).
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plex) between ligand and/or insulin its hexameric state upon
ligand binding, were evaluated as well.
First, we determined the change in 4H3N absorption upon
titration of selected ligand to T6 insulin hexamer preincubated
with this chromophore. Fitting of all curves (Fig. 12) gave Kd,
Bmax, and h values (Table 3) for all types of experiments. The
data fromTable 3 are also presented in a bar plot in supplemen-
tal Fig. S2. The 4H3N spectroscopic data indicate that phenol is
the strongest binder to insulin hexamers, about 4 stronger
than serotonin (Kd values of 0.85mM and 3.34mM, respectively;
see Table 3). In contrast, titration of the same T6 insulin hex-
amers by arginine and dopamine did not induced any changes
in the 4H3N absorption spectra (data not shown), indicating a
lack of binding to site I and, subsequently, inability to induce
T63T3R3/R6 transitions.
The addition of phenol or serotonin to insulin/4H3N that
was also preincubated with 5 mM Arg resulted, however, in
different patterns of binding curves (Fig. 12, C and D), com-
pared with sole ligands-insulin/4H3N titrations (Fig. 12, A and
B). Similar trendswere observed for phenol and serotonin titra-
tions of insulin/4H3N preincubated with 5 mM dopamine (Fig.
12 E and 11F). It seems that in both cases the preincubation of
insulin/4H3N with arginine or dopamine (which are not hor-
mone Site I binders on their own) lowers the phenol Kd to 0.75
and 0.64 mM, respectively. In contrast, arginine and dopamine
do not change the binding affinity of serotonin to insulin hex-
amers (Table 3, Fig. 12A).
The higher Bmax value for phenol than for serotonin (0.17
versus 0.11) may also indicate that serotonin is not able to fully
induce the R6 state of the hexamers. Note that preincubation of
insulin/4H3N with arginine or dopamine lowers the Bmax val-
ues of phenol or serotonin binding to insulin (Fig. 12B). TheHill
coefficient of phenol binding to insulin hexamers (Fig. 12C) is
also higher (h  2.2) than that for serotonin (1.6), indicating a
lower degree of cooperativity for serotonin-insulin interac-
tions. Interestingly, the presence of arginine or dopamine low-
ers cooperativity (i.e. the h value) of phenol-insulin binding but
increases the h value for serotonin interactions with the hor-
mone. This effect seems to be even more noticeable in the case
of dopamine (h 7.1), but these data are accompanied by a high
experimental error (see Table 3 and supplemental Fig. S2).
Discussion
Our parallel and independent MD simulations, X-ray crys-
tallography, and ligand binding experiments provide a concise
picture showing that the insulin hexamer can accommodate
and be affected by ligands that are present in the hormone stor-
age LDCV granules in pancreatic -cells. These ligands can be
of endogenous origin, such as neurotransmitters (serotonin or
dopamine) involved in regulation of insulin secretion, or they
can be byproducts of pro-hormone/pro-insulin processing (e.g.
arginine) that accumulate in the granules.
All the above methods indicated that serotonin is a good
phenol-compatible ligand for insulin hexamer site I, whereas
dopamine is not a site I binder. Serotonin-site I binding engages
its phenolic OH in “phenol-canonic” HBs to CO of CysA6 and
NH of CysA11. This is despite an 29o tilt of its indole plane
with respect to the phenol benzene ring, a movement of the
aromatic moiety that is also observed (to a different degree) in
Tylenol (23), paraben (29), and benzamide (25) complexes.
However, the side chains of the latter phenolic ligands are ori-
ented toward the central channel of the hexamer, whereas the
aminoethyl group of serotonin points into the opposite direc-
tion, i.e. toward the surface of the hexamer. This results in fur-
ther enhancement of serotonin stability in site I by fixing its side
chain via HBs with the CO of CysA11 and carboxyl of GluB21.
The fitting of serotonin in site I is completed with a strong
HisB5-N2-pyrrole contact. The firmness of serotonin-site I
interactions, which is propagated likely toward theN termini of
the B-helix, combined also with a very good overall fit of sero-
tonin into site Imay be behind the induction of the R (i.e.not Rf)
conformation of the T3R3 hexamer. This is rather unique, as
this type of insulin quaternary arrangement occurs mainly in
the T3R
f
3 state. T3R3 hexamers were observed only within a
R63T3R3 retrograde conformational change (39–41) upon
evaporation of phenol from R6 insulin crystals, which is a pro-
cess that cannot occur for the non-volatile serotonin ligand.
Therefore, the stability of the SerInsT3R3 complexmay indicate
that this hormone’s conformer is indeed close to its putative
native form in pancreatic LDCV (as postulated, for example, by
Dunn (26)). Moreover, larger Bmax and Hill coefficient h values
(obtained from 4H3N spectroscopy studies) for phenol as com-
paredwith serotonin suggest that the latter, despite its “perfect”
fit into site I, cannot fully induce the insulin R6 state (as also
confirmed by the lack of R6 serotonin hexamer crystals even at
a very high ligand concentration). These findings further cor-
roborate the potential physiological aspect of the T3R3 insulin
conformer as the only possible oligomeric species in the pres-
ence of serotonin. Although MD simulations did not exclude
the presence of a stable SerInsR6 conformer, the R6 state was
postulated in the MD work a priori (due to its thermodynamic
superiority in the presence of phenol ligands) to identify the
potential ligand-binding sites rather than to investigate the
impact of a particular ligand on the state of the insulin hexamer.
The lack of stable site I-dopamine complexes was demon-
strated by all methods employed in this study. It seems that this
is not due to a steric ligand-cavity incompatibility, as the dop-
Figure 11. Arginine binding sites in the insulin InsSerArgT3R3 hexamer.
Labeling and color-coding is as in Fig. 8, with Cl ion as yellow.
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amine dispersion contribution to free energy of binding in
the MD simulations is more negative compared with phenol.
Rather, as the superposition of dopamine with phenol or sero-
tonin ligands in site I suggests, the lack of dopamine binding is
due to an electrostaticmismatch, namely its inability to accom-
modate the charged aminoethyl side chain in the site I cavity.
The smaller aromatic scaffold of dopamine thus does not allow
its side chain to reach the hexamer surface and form HBs
observed in serotonin complexes.
As the 4H3N spectroscopic applicability was limited here to
the environment of HisB10 and, hence, the site I, the evidence
for other insulin site-ligand interactions came solely from MD
simulations and X-ray crystallography. Both showed serotonin
binding to surface site III, whereas only MD calculations pre-
dicted the possibility of a stable site III-dopamine complex
(note, however, that dopamine-insulin co-crystallization may
be hampered by a rapid chemical degradation/oxidation of
dopamine). Interestingly, MD calculations indicated superior
dopamine binding to site III, with its Kd 50 times better than
for phenol or serotonin. MD-predicted dopamine dominance
at site III is interesting, as these simulations show its binding in
a similar mode to serotonin-site III complex, which is observed
both in MD simulations and crystal structures. Both neu-
rotransmitters engage TyrA14 and GluA17/ArgB22 side chains
Figure 12. Titration of insulin hexamers and 4H3N with phenol (A) or serotonin (B). Titration of insulin hexamers and 4H3N preincubated with 5 mM arginine
with phenol (C) or serotonin (D). Titration of insulin hexamers and 4H3N preincubated with 5 mM dopamine with phenol (E) or serotonin (F). All measured
binding curves are shown.
Table 3
Values of Kd, Bmax, and Hill coefficient (h) for the interaction of phenol or serotonin with insulin hexamers in the presence of 4H3N and/or arginine
and serotonin
Ligand K
d
 S.D. Bmax S.D. h  S.D.
mM
Phenol (n  4) 0.86  0.13 0.17  0.01 2.22  0.30
Phenol and 5 mM Arg (n  3) 0.75  0.01 0.10  0.00 2.07  0.19
Phenol and 5 mM dopamine (n  3) 0.64  0.06 0.13  0.01 1.68  0.18
Serotonin (n  3) 3.34  0.52 0.11  0.08 1.63  0.10
Serotonin and 5 mM Arg (n  3) 3.12  0.31 0.06  0.00 2.64  0.27
Serotonin and 5 mM dopamine (n  3) 3.93  1.28 0.05  0.04 7.12  7.50
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from 2-fold symmetry-related dimers in the network of HB and
-stacking interactions. Moreover, crystal structures of
InsSerT3R3 also underline the dynamical character of site
III mode of binding, which involves flipping of the serotonin
indole ring (i.e. swapping positions of -OH and the aminoethyl
side chain) and a certain variability of the TyrA14-OH/GluA17/
ArgB22 HB patterns.
The impact of these ligands, which are natural components
of pancreatic -cells insulin-storing LDCVs, was also extended
fromneurotransmitters to probing of arginine-insulin hexamer
interactions. It was postulated earlier that arginine can accu-
mulate in these granules upon processing of pro-insulin at its
two sites (Arg-31–Arg-32 and Lys-64–Arg-65) (34, 35), which
are cleaved by specific convertases during maturation of this
hormone (42, 43). Here, the X-ray crystallography revealed
that arginine can penetrate serotonin-containing hexa-
mers (InsSerArgT3R3) without significant changes to their
InsSerT3R3 state. Arginine is accommodated there in channels
within the T3 trimer, parallel to the hexamer 3-fold axis and
opposite to R3 trimer sites I filled by serotonin, which leads to
filling the voids around Zn2 and His-B10. Binding of arginine
in InsSerArgT3R3 is dynamic with high mobility and alterna-
tive, slightly different ligand conformations. The flexibility of
arginine is concentrated mostly around its -CNH2COO

moieties, which formweak alternativeHB tomain chain groups
of CysB7 andHisB5, also exhibiting some flipping around theC
atom. In contrast, the guanidinium groups of the arginines are
firmly engaged in extensive networks of HBs, which link them
with side chains of GluB13, the side- and main-chain of HisB10,
and the side chain of SerB9. This simultaneous binding of the
two very different ligands to the T3R3 insulin hexamer polarizes
this oligomer even further into two structurally distinct trimers,
Arg3T3 and Ser6R3. Although Arg binding in the ArgT3 trimer
has a notable impact on the stability of the usually mobile
GluB13 side chains, the solvent-exposed flexible -CNH2COO

moietiesmay contribute to the disorder of theN-terminal parts
of B-helices, which is, however, untraceable up to the HisB5 site
in both arginine-containing and arginine-free serotonin com-
plexes. In contrast, theGluB13 side chains are fully disordered in
the Ser6R3 trimer, whereas the serotonins in sites I facilitate
fixing of the B1-B19 helices in the R-state.
The structural partition of Arg3T3 and Ser6R3 is more com-
plex. First, although the site I pocket is mainly formed by two
R-monomers, the T-state monomer also contributes here by
LeuB17 and GluB21 toward serotonin aromatic rings and side-
chain binding, respectively. Secondly, serotonin surface site III
alsomediates the structural interface betweenT3 and R3, as this
binding site (formed by TyrA14/GluA17) is provided by the T-
and R-monomers from the 2-fold symmetry related dimers.
Interestingly, 4H3N spectroscopic data indicate that the
presence of arginine increases (13%) phenol (but not sero-
tonin) affinity for site I and also increases the cooperative char-
acter of serotonin binding (as demonstrated by a higher Hill h
factor). These structural and spectroscopic data provide evi-
dence for the T3-R3 trimers cross-talk and, as postulated previ-
ously, for a heterotropic allostery within the insulin hexamer
(22, 30, 44–47). However, the exact molecular detail behind
this phenomenon has been elusive, likely involving a network of
propagating longer range interactions, which fit the Seydoux,
Malhotra, and Bernhard (SMB) cooperativity model (48). The
stabilizing effect of guanidinium groups on GluB13-HisB10 and
Zn2 may be one of the initial steps in this process, priming the
other half of the hexamer for more effective serotonin binding
(i.e. an element of the so-called half-site reactivity). The stabil-
ity of InsSerArgT3R3 and InsSerT3R3 hexamers in the presence
of physiological ligands, i.e. trapping of these oligomers in a
stable T3R3 state, agrees also with the finding that conforma-
tional fluctuations of the T3 trimer needed for the appearance
of site I become constrained upon formation of T3R3 (49). This
can be considered as one of the features of the negative coop-
erativity effect in the insulin hexamer, predicted by the SMB
model as well.
The present 4H3N spectroscopic data also suggest a dop-
amine-lowering effect of phenol’s Kd. As there is no evidence
for dopamine site I binding, this allosteric effect may result
from longer-range cross-talk of the dopamine-site III complex
with the environment of site I. On the other hand, dopamine
does not seem to significantly change the serotonin Kd, and
therefore, some “competitive” crowding effect (e.g. dynamic
occlusion of site I) between these twoneurotransmitters cannot
be excluded. It may also mean that dopamine-site III binding
facilitates the diffusion of a smaller ligand (i.e. phenol) into site
I, whereas the increased stability of the insulin R3-like trimer
(via new HBs and interactions in site III) may obtrude its effect
on binding of a larger ligand (such as serotonin).
It is worthmentioning that several tubular electron densities
are also observed in InsSerArgT3R3 on the top of the T3 trimer.
These are linked with the modeled arginine ligands, suggesting
the presence of more of these molecules on the hexamer sur-
face, in the form of a hydrogen-binding network of ligands.
Some of this electron density is in contact with the T3Zn
2 ion.
Therefore, a contribution of the arginine -COO group to the
tetrahedral/monodentate coordination of Zn2 (observed also
in the insulin R6 structure; Ref. 41) cannot be excluded either.
This direct arginine-Zn2 interaction would hamper the
T33R3 transition even further, thus reinforcing the stability of
the T3R3 hexamer.
Arginine is widely used in vitro as a nonspecific protein-
folding stabilizing agent (49, 50), and so its presence in
InsSerArgT3R3 structures may reflect some of its physiologi-
cally relevant roles as a ubiquitous insulin ligand. First, it may
serve as an unspecific, granules-abundant, insulin-folding sta-
bilizer and hexamer half-life enhancer. Second, it may act as a
more specific endogenous ligand that modulates the hexamer
cooperativity, also enhancing the stability of its particular T3R3
storage form. This more specific role of arginine may result,
among others, from its guanidinium counterion-like neutral-
ization of the repulsive system of the GluB13 side chains in the
hexamer core. Moreover, a simultaneous arginine-mediated
cross-linking of GluB13 side chains with Zn2-binding HisB10,
leading to stabilization of this structurally key region, further
exemplifies the ligand-like role of this amino acid.
It has to be stressed that insulin crystallization in the granules
can be also affected by the intragranular Zn2 concentrations,
which are modulated by some Zn2 transporters (ZnT), espe-
cially by the disease-associated ZnT8 variants (51). However,
Structural forms of storage insulin in pancreas
J. Biol. Chem. (2017) 292(20) 8342–8355 8351
 at U
N
IV
ERSITY
 O
F Y
O
RK
 on June 1, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the focus here was on insulin/neurotransmitter interactions,
hence the experimental Zn2 concentrations (0.4–8mM) were
maintained within typical insulin in vitro crystallization ranges.
Interestingly, insulin crystallized here only in the formof 2Zn2
hexamers, regardless the very high (25:1) Zn2-hormonemolar
excess in the crystal-yielding conditions.
There are ongoing efforts for a better insight into the size and
content of insulin storage granules (e.g. Ref. 52). Their exocyto-
sis can also be morphologically and mechanistically quite het-
erogeneous (so-called “kiss-and-run” phenomenon), releasing
varying amounts and forms of granule content and on different
time scales (53). Therefore, the final amount and formof insulin
discharged to the circulation can be a very complex and multi-
factorial process; whether insulin-neurotransmitter-arginine
hexamers are one of its variables remains to be seen.
Conclusions
We have demonstrated here that insulin oligomeric forms in
storage granules in -pancreatic cells could be regulated by
certain endogenous components of these vesicles, such as sero-
tonin, dopamine, and arginine. They are able to (i) shift the
insulin oligomeric equilibrium toward the T3R3 state, which
thereforemay be considered as the insulin storage form in pan-
creatic -cells, (ii) affect andmodulate the allostery of the insu-
lin hexamer, (iii) may provide folding stability and protection
for the insulin hexamer, and consequently (iv), may have a
direct role in the modulation of insulin release from -cells in
vivo. Moreover, these ligands can act in a synergistic, hetero-
tropic fashion, pointing to a co-operative, complex, and
dynamic nature of the interactions within the insulin hexamer.
Therefore, the importance of the neurotransmitters for insu-
lin beta-cell biology can be either cumulative or even indepen-
dent. Serotonin/dopamine are involved in the regulation of
exocytosis of the granules, whereas their impact on insulin stor-
age can be seen as a serendipitous side effect of the evolution of
the hormone within the -cell environment and its optimiza-
tion for a particular, species-specific, physiological profile.
It is also tempting to consider serotonin/dopamine-human
insulin interactions as molecular fingerprints of insulin evolu-
tion in the animal kingdom, as insulin-like hormones are
expressed in neurons in many invertebrates (54). The newly
discovered (and still puzzling) role of insulin in the central nerv-
ous system and the emergence of neurodegeneration-linked so-
called type III diabetes thus places our findings in amuchwider
physiological context (55, 56).
In summary, we show here that the insulin hexamer can act
as amacromolecular sponge, keen to bind and assimilate a vari-
ety of physiological ligands and ions. This suggests that clinical
exploration and use of insulin-hexamer-stabilizing ligands,
driven by steering of the pharmacokinetics of this hormone,
may mirror its physiological canonical properties, rooted also
in insulin evolution. Although the present work is aimed at
shedding new light on the physiological storage state of this
hormone, it may also open ways to novel approaches in med-
ical formulations of insulin, toward its more desired closer to
in vivo profile during subcutaneous injections administered
in diabetes.
Experimental procedures
Molecular dynamics simulations
All MD simulations were performed using the AMBER 14
program (57, 58). In all simulations the AMBER ff03 protein
force field (59) and SPC/E watermodel were used (60). Produc-
tion simulations were performed in the isothermal-isobaric
ensemble at ambient conditions of T  300 K and p  1 atm
using the Berendsen barostat and thermostat (61). The only
exception was thermodynamic integration calculations, where
the temperature was controlled by a Langevin thermostat with
a reference temperature of T  300 K and a collision frequency
of 5 ps1 in order to avoid problems of non-ergodicity when the
ligand is fully decoupled from its environment. 3D periodic
boundary conditions were applied with a non-bonded interac-
tion cutoff of 9 Å. The long-range electrostatic interactions
were accounted for using the particle mesh Ewald method (62)
using a cubic spline interpolation. The density of the charge
grid was 64  64  64, and the direct sum threshold was 105.
Van der Waals interactions beyond the cutoff were treated
using the continuummodel correction for energy and pressure.
All bonds containing hydrogen atoms were constrained using
the SHAKE algorithm (63). A time step of 2 fs was employed.
Mildly acidic conditions (pH  5.5) of insulin storage gran-
ules would generally tend to favor a fully protonated side chain
of HisB5 (64). However, due to zinc coordination the N2 atom
of HisB10 is actually deprotonated (65, 66). In addition, the six
GluB13 side chains in the middle region of the insulin hexamer
were considered as deprotonated. The overall charge of the
protein is, therefore, 6. Initial simulations indicated diffusion
of Na cation/cations into the middle region. At least one Na
cation was always present in the middle region of the hexamer
being placed to the middle region from the start of the
simulation.
Substitution of the site I-bound phenol by the neurotrans-
mitters serotonin or dopamine was also investigated. The
R6-state insulin complex with six phenols in sites I (referred to
here as InsPheR6) was used as a reference structure (PDB ID
1AIY) due to a higher stability of this conformer and homoge-
nous saturation of insulin hexamer with the same ligand (67).
The starting structures for simulations were obtained by
exchanging phenol molecules in site I by either dopamine or
serotonin molecules with two initial conformations for each
ligand. The ligands were built from the phenol core (1 oxygen
atom and 6 carbon atoms), the structure of which was available
from X-ray structure). Subsequent restrained minimization
eliminated any potential steric clashes. Starting geometries of
phenolic ligands inside the phenolic pockets are depicted in
Fig. 2.
Phenol, serotonin, and dopamine were assigned parameters
from ff03AMBER force field using theANTECHAMBERpack-
age (68). Both serotonin and dopamine have a charge of1 e at
pH 5.5. Partial atomic charges were obtained by the RESP
(Restrained Electrostatic Potential Fit) (83) method, calculated
at the HF/6–31G level, and they are listed in supplemental
Table S2, with the explanation in the supplemental Figure S5.
These calculationswere performedusing theGaussian 09 pack-
age (69).
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The B10-Zn interaction potential had to be re-parametrized
in order to account (at least partially) for the electronic polar-
ization and charge transfer effects and thus to reproduce exper-
imental data. The charges on zinc ions andonHisB10weremod-
ified according to the results from ab initio calculations on
small model systems to 1.5 e and 0.1677 e, respectively.
These were obtained using the RESP/NPA (Natural Population
Analysis) (84) analysis employing the B3LYP/aug-cc-pvtz level
of theory (85, 86). In a similar spirit, to account for electronic
polarization effects in a mean-field way (70–73), we rescaled
bulk Na and Cl (including the Na cation located in the
middle of the hexamer) ionic charges by a factor of 0.75.
Each of the liganded insulin R6 hexamers was immersed into
a unit cell containing 9000 SPC/E water molecules, with Na/
Cl ions added to acquire overall electroneutrality with no
excess of salt present. After preparation, the energy of each of
the systems was minimized using 5000 steps of the steepest
descent method, where the protein and phenolic ligands were
restrained with a harmonic potential. The systems were then
subjected to 200 ps of isothermal-isochoric molecular dynam-
ics, where the temperature was slowly raised from 10 to 300 K.
This was followed by 1.2 ns of an isothermal-isobaric equilibra-
tion, which led to an equilibrated cell size of69 68 66 Å3.
Systems were assessed as equilibrated by monitoring tempera-
ture, cell size, density, and root mean square displacement
of the protein. After equilibration, the production runs were
propagated for 600 ns.
In addition to directMD simulations free energy calculations
employing the thermodynamic integration method were per-
formed to determine apparent binding constants Kd of phenol
and the two neurotransmitters to the R6 hexamer. The free
energy cycles and further details of these simulations are pre-
sented in the supplemental Figs. S6 and S7, and Table S3. Sim-
ilar free energy calculations for evaluation of the Kd values to
ligand binding sites III were performed using the umbrella sam-
pling methods (for more details see the supplemental informa-
tion, and Table S4). Here, to stabilize the hexamer R6 state, site
I was filled with phenol before the search for dopamine site III
binding mode, as this neurotransmitter did not bind to site I in
MD simulations.
X-ray crystallography
Crystallizations of all insulin complexes reported here were
performedwith the in-house insulin crystallization screens that
cover most of the previously reported crystal growth parame-
ters. Crystallization conditions, data collection, refinement,
and models statistics as well as PDB codes are provided in sup-
plemental Table S1. All crystals were directly flash-cooled in
liquid N2. X-ray data were collected at 100 K and processed by
xia2 (74), and model building and refinement (F0
F) were
performed by COOT (75) and the CCP4 suite of programs (76).
Crystal structures were solved by Molrep (77) with the B1-B6-
truncated insulin hexamer, hexamer-derived dimer, and insu-
lin monomer as a model (based on PDB ID 1MSO; Ref. 78) and
refined by Refmac 5.8 (79). Examples of electron density maps
are shown in supplemental Figs. S3 and S4. The figures were
made using CCP4mg (80). For structural comparisons, all insu-
lin hexamer structures were superimposed in COOT by the
SSM fit option. For comparison of the site I ligand-binding
modes, the relevant dimers were superimposed by C match-
ing of the B9–19 helix for one of the monomers by the LSQ
option in COOT.
Determination of ligand Kd values by a solution 4H3N assay
Solution studies of the interactions of phenol, serotonin,
dopamine, and arginine with porcine insulin were performed
following the protocols by Huang et al. (81), Bloom et al. (82),
and Huus et al. (46). An anionic ligand 4H3N was used as a
sensitive chromophoric probe to determine ligand binding
curves by monitoring UV-visible absorption. 4H3N binds only
in the insulin R-state (in the vicinity of HisB10), which red-shifts
its absorption spectrum. The samples were dissolved in 10 mM
potassiumphosphate buffer at pH7.4. In allmeasurements por-
cine hexameric Zn2-insulin (two atoms of zinc per one hex-
amer) and 4H3Nwere used at 0.6mM and 0.225mM concentra-
tions, respectively. Insulin was preincubated with 4H3N in a
total volume 0.6ml for 20min at room temperature, afterwhich
a particular ligand (phenol, serotonin, dopamine, or arginine)
was added in a minimum volume (0.6–3 l) of 10 mM potas-
sium phosphate buffer. After 15 min of reverse transcription
equilibration, theUV-visible absorbance spectra were collected
on a Perkin, Lambda 25 UV-visible Spectrometer. The spectra
were taken in the range of 300–550 nm, and the difference
spectra at max of 444 nm were obtained by subtracting the
absorbance of ligand-free 4H3N from the absorbance of ligand-
bound 4H3N. The binding curves were analyzed using a
method of non-linear regression and a fitting program consid-
ering one-site specific bindingwith aHill slope usingGraphPad
Prism 5.0. The final Kd, Bmax, and h values with standard errors
were calculated from at least three independently determined
binding curves for each system.
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